Balyasny Asset Management
CADL icon

Balyasny Asset Management’s Candel Therapeutics CADL Stock Holding History

Balyasny Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
+43,208
New +$235K ﹤0.01% 2684
2025
Q4 		– Sell
-49,483
Closed -$252K – 3119
2025
Q3 		$252K Buy
+49,483
New +$286K ﹤0.01% 2641
2025
Q2 		– Sell
-37,710
Closed -$213K – 2862
2025
Q1 		$213K Buy
+37,710
New +$308K ﹤0.01% 2567

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's CADL Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 43,208 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #2684 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in CADL as recently as Q3 2025.

Balyasny Asset Management first reported a position in CADL in Q1 2025 and has held it in 3 quarters since. The position peaked at $252K in Q3 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Balyasny Asset Management held 43,208 shares of Candel Therapeutics worth $212K as of Q1 2026.
  • Candel Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2684 holding.
  • Balyasny Asset Management first reported a position in Candel Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Balyasny Asset Management's Candel Therapeutics position peaked at $252K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.